202 related articles for article (PubMed ID: 10673751)
1. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia.
Eckert C; Landt O; Taube T; Seeger K; Beyermann B; Proba J; Henze G
Leukemia; 2000 Feb; 14(2):316-23. PubMed ID: 10673751
[TBL] [Abstract][Full Text] [Related]
2. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
4. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
Nakao M; Janssen JW; Flohr T; Bartram CR
Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
[TBL] [Abstract][Full Text] [Related]
5. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes.
Eckert C; Scrideli CA; Taube T; Songia S; Wellmann S; Manenti M; Seeger K; Biondi A; Cazzaniga G
Leukemia; 2003 Dec; 17(12):2517-24. PubMed ID: 14562127
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
7. [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
Zhang YT; Luo ZF; Fang JP; Guo HX; Huang K; Li CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1235-9. PubMed ID: 21129267
[TBL] [Abstract][Full Text] [Related]
8. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG
Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847
[TBL] [Abstract][Full Text] [Related]
10. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.
Taube T; Eckert C; Körner G; Henze G; Seeger K
Leuk Res; 2004 Jul; 28(7):699-706. PubMed ID: 15158091
[TBL] [Abstract][Full Text] [Related]
11. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
12. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia.
Verhagen OJ; Willemse MJ; Breunis WB; Wijkhuijs AJ; Jacobs DC; Joosten SA; van Wering ER; van Dongen JJ; van der Schoot CE
Leukemia; 2000 Aug; 14(8):1426-35. PubMed ID: 10942239
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
14. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
Liu JY; Li ZG; Gao C; Cui L; Wu MY
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
[TBL] [Abstract][Full Text] [Related]
16. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.
van der Velden VH; Wijkhuijs JM; Jacobs DC; van Wering ER; van Dongen JJ
Leukemia; 2002 Jul; 16(7):1372-80. PubMed ID: 12094263
[TBL] [Abstract][Full Text] [Related]
17. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
18. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
[TBL] [Abstract][Full Text] [Related]
19. Real-time quantitative PCR: standardized detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Polymerase chain reaction.
Pine SR; Moy FH; Wiemels JL; Gill RK; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2003 Feb; 25(2):103-8. PubMed ID: 12571459
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of minimal residual disease in childhood lymphoid malignancies using an allele-specific oligonucleotide real-time quantitative polymerase chain reaction.
Tarusawa M; Yashima A; Endo M; Maesawa C
Int J Hematol; 2002 Feb; 75(2):166-73. PubMed ID: 11939263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]